KONEXBiotech & Pharma322970

Moogene Medi

₩1,830▼ 0.49%2026-11-18 close
Market Cap
₩18.5B
Turnover
₩1,425,196
Volume
765 shares
Shares out.
10.1M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

LNP hair-loss trial amid persistent losses

Moogene Medi is a loss-making biotech whose LNP hair-loss drug trial and balance-sheet repair are advancing at the same time.

  1. 1

    Revenue reached KRW 1.41 billion in 2025, a sharp increase, yet the operating loss of KRW 1.58 billion kept the company in deficit.

  2. 2

    A co-development agreement for AD-303 was signed in December 2025 with three companies, dividing clinical and commercialization roles.

  3. 3

    In March 2026 the company decided on a KRW 5 billion convertible bond and an KRW 1.1 billion rights-free capital raise to fund debt repayment.

  4. 4

    As of year-end 2025, the equity ratio stood at 26.28% and the borrowing dependence ratio at 58.75%, indicating a heavy financial burden.

  5. 5

    The share price moved from 2,795 KRW on March 31, 2026 to 1,850 KRW at the current quote on November 11, 2026.

02

Business structure

Moogene Medi is a nano-medicine company that uses lipid nanoparticle (LNP) technology to deliver genes, proteins and synthetic drugs into cells. The company was founded in June 2016 and listed on the KONEX market on June 24, 2020.

According to a 2024 technology evaluation report, its operations are organized into a bio part, a materials part and a development support unit. The bio part develops biopharmaceuticals with high therapeutic potential, while the materials part develops bio-materials that apply nano-technology.

The pipeline consists of the topical male-pattern hair-loss drug HUTERA (AD-303) and treatments for colorectal and pancreatic cancer. On a corporate-information aggregator basis, the 2025 business mix was 92% male-pattern hair-loss drug and 7% cosmetic raw materials and skin medical devices.

The topical format was chosen to reduce the systemic side effects of oral treatments and to target hair follicle cells selectively. LNP is the technology used in mRNA vaccines, and patent disputes among overseas companies in this field are intense.

The company says its proprietary LNP avoids existing patents and reaches delivery efficiency similar to overseas patented formulations. Its cosmetics business, which received a manufacturing registration in March 2025, is expanding mainly through raw-material supply. Compared with large listed biotech companies, however, its capital and revenue scale remain small.

03

Recent trends

Moogene Medi's revenue has long consisted mainly of research services and sample sales. According to aggregator data, revenue was roughly KRW 7 million in 2021, KRW 20 million in 2022, KRW 140.03 million in 2023 and KRW 116.52 million in 2024.

Revenue in 2025 reached KRW 1.41 billion, up 1,110% year on year, although the drivers of the increase are only partly disclosed. The 2025 operating loss of KRW 1.58 billion was narrower than the KRW 2.92 billion loss recorded in 2024.

The operating margin improved to -112.32% from -2,504.61% in 2024, but costs remain large relative to sales. The 2025 net loss of KRW 1.47 billion was smaller than the KRW 6.23 billion loss in 2024. At the end of 2025, total equity stood at about KRW 2.54 billion against total liabilities of about KRW 7.11 billion.

In December 2025 the company signed a co-development agreement for its male-pattern hair-loss drug with Yuhan, JW Pharmaceutical and Medicakorea, with the contract value undisclosed.

On March 12, 2026 the company decided on a KRW 5 billion convertible bond placed privately with Yuhan, with a conversion price of 2,620 KRW. On March 13, 2026 it decided on a third-party rights offering of about KRW 1.1 billion, with proceeds used to repay loans from individual lenders.

The share price fell from 2,795 KRW on March 31, 2026 to 1,850 KRW at the current quote on November 11, 2026. The all-time low of 1,350 KRW was recorded on July 3, 2024.

04

Outlook

The outlook depends largely on how fast the hair-loss drug trial progresses and on the company's access to funding. AD-303 received approval for a Phase 1/2a clinical trial plan on August 14, 2025. The company plans a 30-subject Phase 1/2a study at the clinical trial center of Seoul National University Hospital.

It intends to set an appropriate dose after securing safety and pharmacokinetic and pharmacodynamic data, and then to demonstrate efficacy in a Phase 3 study.

In an interview published in 2025, the CEO indicated that commercialization could be possible in the second half of 2026, but the trial remains at the Phase 1/2a stage.

The conversion period for the March 2026 convertible bond runs from March 26, 2027 to February 26, 2029, which keeps the possibility of share issuance open. Full operation of the Hanam GMP production facility is also cited as a precondition for revenue growth.

The company has presented a strategy that uses improved-formulation drugs as early cash generators while pursuing technology transfers. A structure in which co-development partners share clinical and commercialization costs can ease financial pressure. However, as long as losses and the high debt ratio persist, reliance on external funding will remain.

05

Bull factors

Hair-loss drug enters clinical stage

The topical male-pattern hair-loss drug AD-303 received approval for a Phase 1/2a clinical trial plan from the Ministry of Food and Drug Safety on August 14, 2025. The company plans to enroll 30 subjects at the clinical trial center of Seoul National University Hospital.

It intends to confirm safety and an appropriate dose before moving to Phase 3 to demonstrate efficacy. Its formulation, which aims to reduce the systemic side effects of oral treatments, is presented as the key differentiator.

Co-development splits commercialization roles

On December 12, 2025 the company signed a co-development agreement for AD-303 with Yuhan, JW Pharmaceutical and Medicakorea. Moogene Medi is responsible for formulation technology, clinical execution, reporting of trial results and support for product approval.

The partners carry out clinical work and commercialization and hold sales and marketing rights. The contract term is reported as ten years from the first commercial sale, and the contract value is undisclosed.

LNP patents and platform expansion

The company holds a US patent covering LNP-based treatment for type 2 diabetes and a topical hair-loss treatment. It also says it has secured hair-loss treatment patents in the United States and Australia. The company expects its LNP platform to deliver proteins and synthetic drugs as well as gene-based therapies. This platform scalability is cited as a basis for expanding partnerships.

06

Bear factors

Persistent operating losses

The 2025 operating loss was KRW 1.58 billion and the net loss was KRW 1.47 billion. The operating margin of -112.32% shows that costs remain heavy relative to sales. At the end of 2025 total equity was roughly KRW 2.5 billion, against total liabilities of roughly KRW 7.1 billion. The losses narrowed from 2024, but no timeline for reaching profitability has been given.

Funding needs and dilution risk

In March 2026 the company decided on a KRW 5 billion convertible bond and a rights offering of about KRW 1.1 billion, with proceeds used partly to repay debt. The bond's conversion price is 2,620 KRW, with a minimum adjusted price of 2,096 KRW.

Conversions and share issuances would increase the number of shares outstanding and could dilute existing shareholders. Funding is repeatedly tied to new share issuance.

Possible delay in commercialization

In an interview published in 2025, the CEO projected commercialization of the hair-loss drug in the second half of 2026. However, the August 2025 approval covered only a Phase 1/2a trial plan, and the company has stated that Phase 3 is needed to demonstrate efficacy.

Clinical results and the product approval process still lie ahead before any launch. Depending on funding conditions, the timeline could slip.

07

Risk factors

Macro

Funding conditions for biotech companies move with interest rates and sentiment in the KOSDAQ and KONEX capital markets. Given its high borrowing dependence and modest equity ratio, Moogene Medi is sensitive to changes in external financing conditions.

Trading value on November 11, 2026 was KRW 3,580,570, indicating a thin market. Thin trading can amplify share-price volatility.

Clinical & regulatory

An IND approval only permits clinical trials to start and does not establish efficacy. Phase 3 design and the timing of launch could change depending on Phase 1/2a results. The company has mentioned the possibility of selling under conditional approval, but that depends on regulatory decisions. Although a topical product may allow a shorter trial period, safety evaluation remains essential.

Liquidity & dilution

If bond conversions and share issuances continue, the number of shares outstanding will increase. The March 2026 rights offering converted loans from individual lenders into equity, which materially changes the shareholder structure.

The convertible bond includes a price-adjustment clause that could apply if the share price falls below the conversion price. Because the stock trades in small volumes on KONEX, large sell orders could cause significant price moves.

08

Overall view

Moogene Medi combines LNP delivery technology and a hair-loss drug in clinical development with a thin revenue base and continuing losses. The 2025 operating loss of KRW 1.58 billion and net loss of KRW 1.47 billion narrowed from 2024 but remain large relative to its equity base.

On the positive side, the key points are the Phase 1/2a approval for AD-303, the co-development structure with Yuhan and other partners, and the US patents.

On the negative side, the high-debt balance sheet, the possible increase in shares from the 2,620 KRW convertible bond and rights offering, and the risk of a longer path to commercialization stand out. Funds raised in March 2026 have been used to repay part of the debt, so balance-sheet repair is underway.

However, the extent and durability of that improvement will depend on clinical results and further access to funding. The share price moved from 2,795 KRW on March 31, 2026 to 1,850 KRW at the current quote, a path that reflects how the market is reacting to funding and clinical timing.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 10 more articles and sources
  1. m.news.nate.com
  2. jobkorea.co.kr
  3. kind.krx.co.kr
  4. prestocknews.com
  5. hitnews.co.kr
  6. m.news.nate.com
  7. m.news.nate.com
  8. pharm.edaily.co.kr
  9. businessreport.kr
  10. tradingview.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis